Institutos Universitarios

  1. Portada
  2. GRUPOS DE INVESTIGACIÓN
  3. GRUPO JAVIER FERNÁNDEZ RUÍZ
  4. PUBLICACIONES

PUBLICACIONES

 

 

PUBLICACIONES

 

  • 2023

 

         Thienopyrimidine Derivatives as GPR55 Receptor Antagonists: Insight into Structure-Activity Relationship.

           Figuerola-Asencio L, Morales P, Zhao P, Hurst DP, Sayed SS, Colón KL, Gómez-Cañas M, Fernández-Ruiz J, Croatt MP, Reggio PH, Abood ME, Jagerovic N.

           ACS Med Chem Lett. 2022 Dec 2;14(1):18-25. doi: 10.1021/acsmedchemlett.2c00325. eCollection 2023 Jan 12
 

         Endocannabinoid-Binding Receptors as Drug Targets.

          Gómez-Cañas M, Rodríguez-Cueto C, Satta V, Hernández-Fisac I, Navarro E, FernándezRuiz J.

          Methods Mol Biol. 2023;2576:67-94. doi: 10.1007/978-1-0716-2728-0_6

 

 

  • 2022


         New Statement about NRF2 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

          Isabel Lastres-Becker, Eva de Lago, Ana Martínez, Javier Fernández-Ruiz

          Biomolecules. 2022 Aug 29;12(9):1200. doi: 10.3390/biom12091200


         Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome

           Cristina Alonso, Valentina Satta, Paula Díez-Gutiérrez, Javier Fernández-Ruiz, Onintza Sagredo       

           Neuropharmacology 2022 Mar 1;205:108914. doi:10.1016/J.NEUROPHARM.2021.108914

 

 

  • 2021

         

 

          Recent advances in the pathogenesis and therapeutics of amyotrophic lateral sclerosis.

           Fernández-Ruiz J, de Lago E, Rodríguez-Cueto C, Moro MA.

           Br J Pharmacol. 2021 Mar;178(6):1253-1256. doi: 10.1111/bph.15348

 

          Targeting the CB2 receptor and other endocannabinoid elements to delay disease progression in amyotrophic lateral sclerosis.

            Rodríguez-Cueto C, García-Toscano L, Santos-García I, Gómez-Almería M, Gonzalo-Consuegra C, Espejo-Porras F, Fernández-Ruiz J, de Lago E.
 
            Br J Pharmacol. 2021 Mar;178(6):1373-1387. doi: 10.1111/bph.15386. Epub 2021 Feb 20
 
          Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease.
 
            Sánchez Montero JM, Agis-Torres A, Solano D, Söllhuber M, Fernandez M, Villaro W, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Egea J,
            Martín MI, Girón R.
 
            Eur J Pharmacol. 2021 Mar 15;895:173875. doi: 10.1016/j.ejphar.2021.173875. Epub 2021 Jan 15
 
          Preclinical investigation of β-caryophyllene as a therapeutic agent in an experimental murine model of Dravet syndrome.
 
           Alonso C, Satta V, Díez-Gutiérrez P, Fernández-Ruiz J, Sagredo O.
 
           Neuropharmacology. 2022 Mar 1;205:108914. doi: 10.1016/j.neuropharm.2021.108914. Epub 2021 Dec 4
 
 
           BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis.
 
            Gómez-Almería M, Burgaz S, Costas-Insua C, Rodríguez-Cueto C, Santos-García I, Rodríguez-Crespo I, García C, Guzmán M, de Lago E, Fernández-Ruiz J
 
            Int J Mol Sci. 2021 Nov 20;22(22):12533. doi: 10.3390/ijms222212533
 
          (+)-trans-Cannabidiol-2-hydroxy pentyl is a dual CB1R antagonist/CB2R agonist that prevents diabetic nephropathy in mice.
 
            González-Mariscal I, Carmona-Hidalgo B, Winkler M, Unciti-Broceta JD, Escamilla A, Gómez-Cañas M, Fernández-Ruiz J, Fiebich BL, Romero-Zerbo SY,
            Bermúdez-Silva FJ, Collado JA, Muñoz E
           
            Pharmacol Res. 2021 Jul;169:105492. doi: 10.1016/j.phrs.2021.105492. Epub 2021 May 19
 
          Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments.
 
             Satta V, Alonso C, Díez P, Martín-Suárez S, Rubio M, Encinas JM, Fernández-Ruiz J, Sagredo O.
 
             Front Mol Neurosci. 2021 Jan 29;13:602801. doi: 10.3389/fnmol.2020.602801. eCollection 2020
 
 
           Neuroprotection with the Cannabidiol Quinone Derivative VCE-004.8 (EHP-101) against 6-Hydroxydopamine in Cell
           and Murine Models of Parkinson's Disease.
 
             Burgaz S, García C, Gómez-Cañas M, Rolland A, Muñoz E, Fernández-Ruiz J.
 
             Molecules. 2021 May 28;26(11):3245. doi: 10.3390/molecules26113245
 
            Inactivation of the CB2 receptor accelerated the neuropathological deterioration in TDP-43 transgenic mice,
            a model of amyotrophic lateral sclerosis.
 
             Rodríguez-Cueto C, Gómez-Almería M, García Toscano L, Romero J, Hillard CJ, de Lago E, Fernández-Ruiz J.
 
             Brain Pathol. 2021 Nov;31(6):e12972. doi: 10.1111/bpa.12972. Epub 2021 May 13
 
           Preclinical Investigation in Neuroprotective Effects of the GPR55 Ligand VCE-006.1 in Experimental Models of Parkinson's Disease
           and Amyotrophic Lateral Sclerosis.
 
             Burgaz S, García C, Gonzalo-Consuegra C, Gómez-Almería M, Ruiz-Pino F, Unciti JD, Gómez-Cañas M, Alcalde J, Morales P, Jagerovic N,
             Rodríguez-Cueto C, de Lago E, Muñoz E, Fernández-Ruiz J.
 
             Molecules. 2021 Dec 16;26(24):7643. doi: 10.3390/molecules26247643
 
           Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease
           using 6-hydroxydopamine-lesioned mice.
 
            Burgaz S, García C, Gómez-Cañas M, Navarrete C, García-Martín A, Rolland A, Del Río C, Casarejos MJ, Muñoz E, Gonzalo-Consuegra C, Muñoz E, 
            Fernández-Ruiz J.
 
            Mol Cell Neurosci. 2021 Jan;110:103583. doi: 10.1016/j.mcn.2020.103583. Epub 2020 Dec 16
 
 
 

  • 2020

 

           Possible therapeutic applications of cannabis in the neuropsychopharmacology field.

             Fernández-Ruiz J, Galve-Roperh I, Sagredo O, Guzmán M.
 
             Eur Neuropsychopharmacol. 2020 Jul;36:217-234. doi: 10.1016/j.euroneuro.2020.01.013. Epub 2020 Feb 10
 
           Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB2 Receptor*.
 
             Morales P, Navarro G, Gómez-Autet M, Redondo L, Fernández-Ruiz J, Pérez-Benito L, Cordomí A, Pardo L, Franco R, Jagerovic N.
 
             Chemistry. 2020 Dec 4;26(68):15839-15842. doi: 10.1002/chem.202003389. Epub 2020 Nov 9.PMID: 32794211
 
          Beneficial effects of the phytocannabinoid Δ9-THCV in L-DOPA-induced dyskinesia in Parkinson's disease.
 
            Espadas I, Keifman E, Palomo-Garo C, Burgaz S, García C, Fernández-Ruiz J, Moratalla R.
 
            Neurobiol Dis. 2020 Jul;141:104892. doi: 10.1016/j.nbd.2020.104892. Epub 2020 May 6
 
           Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
 
             Fernández-Trapero M, Pérez-Díaz C, Espejo-Porras F, de Lago E, Fernández-Ruiz J.
 
             Biomolecules. 2020 Feb 11;10(2):279. doi: 10.3390/biom10020279
 
          Δ9 -Tetrahydrocannabinolic acid alleviates collagen-induced arthritis: Role of PPARγ and CB1 receptors.
 
             Palomares B, Garrido-Rodriguez M, Gonzalo-Consuegra C, Gómez-Cañas M, Saen-Oon S, Soliva R, Collado JA, Fernández-Ruiz J, Morello G,
             Calzado MA, Appendino G, Muñoz E.
 
             Br J Pharmacol. 2020 Sep;177(17):4034-4054. doi: 10.1111/bph.15155. Epub 2020 Jul 8
 
          Neuropathological Characterization of a Dravet Syndrome Knock-In Mouse Model Useful for Investigating Cannabinoid Treatments.
 
            Satta V, Alonso C, Díez P, Martín-Suárez S, Rubio M, Encinas JM,Fernández-Ruiz J, Sagredo O.
 
            Front Mol Neurosci. 2021 Jan 29;13:602801. doi: 10.3389/fnmol.2020.602801. eCollection 2020
 
          Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1δ kinase inhibitor treatment.
 
            Martínez-González L, Rodríguez-Cueto C, Cabezudo D, Bartolomé F, Andrés-Benito P, Ferrer I, Gil C, Martín-Requero Á, 
            Fernández-Ruiz J, Martínez A, de Lago E.
 
            Sci Rep. 2020 Mar 10;10(1):4449. doi: 10.1038/s41598-020-61265-y
 
          Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease
          using 6-hydroxydopamine-lesioned mice.
 
            Burgaz S, García C, Gómez-Cañas M, Navarrete C, García-Martín A, Rolland A, Del Río C, Casarejos MJ, Muñoz E, Gonzalo-Consuegra C, Muñoz E, 
            Fernández-Ruiz J.
 
            Mol Cell Neurosci. 2021 Jan;110:103583. doi: 10.1016/j.mcn.2020.103583. Epub 2020 Dec 16
 
 
 

  • 2019

 

          The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve

          on the poor current therapeutic outcomes.

            Fernández-Ruiz J.
 
            Br J Pharmacol. 2019 May;176(10):1370-1383. doi: 10.1111/bph.14382. Epub 2018 Jul 8
 
         Structure-Effect Relationships of Novel Semi-Synthetic Cannabinoid Derivatives.
 
           Götz MR, Collado JA, Fernández-Ruiz J, Fiebich BL, García-Toscano L, Gómez-Cañas M, Koch O, Leha A, Muñoz E, Navarrete C, Pazos MR, Holzgrabe U.
 
           Front Pharmacol. 2019 Nov 20;10:1284. doi: 10.3389/fphar.2019.01284. eCollection 2019
 
         Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and
         Expected Relevance as Neuroprotective Targets.
 
           Gómez-Ruiz M, Rodríguez-Cueto C, Luna-Piñel E, Hernández-Gálvez M, Fernández-Ruiz J.
 
           Front Mol Neurosci. 2019 Apr 24;12:94. doi: 10.3389/fnmol.2019.00094. eCollection 2019
 
         Morphine self-administration alters the expression of translational machinery genes in the amygdala of male Lewis rats.
 
           Ucha M, Coria SM, Núñez AE, Santos-Toscano R, Roura-Martínez D, Fernández-Ruiz J, Higuera-Matas A, Ambrosio E.
 
           J Psychopharmacol. 2019 Jul;33(7):882-893. doi: 10.1177/0269881119836206. Epub 2019 Mar 19
 
         Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in
         Experimental Parkinson's Disease.
 
          Burgaz S, García C, Gómez-Cañas M, Muñoz E, Fernández-Ruiz J.
 
          Molecules. 2019 Jul 25;24(15):2702. doi: 10.3390/molecules24152702
 
 
         Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice,
         a model of amyotrophic lateral sclerosis.
 
          Espejo-Porras F, García-Toscano L, Rodríguez-Cueto C, Santos-García I, de Lago E, Fernandez-Ruiz J.
 
          Br J Pharmacol. 2019 May;176(10):1585-1600. doi: 10.1111/bph.14216. Epub 2018 May 6
 
 
 

  • 2018

 

        Preface: Why a Special Issue on cannabinoid research in Spain?

          Fernández-Ruiz J.
 
          Biochem Pharmacol. 2018 Nov;157:1-7. doi: 10.1016/j.bcp.2018.10.018. Epub 2018 Oct 21
 
 
         Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system.
 
           Aymerich MS, Aso E, Abellanas MA, Tolon RM, Ramos JA, Ferrer I, Romero J, Fernández-Ruiz J.
 
          Biochem Pharmacol. 2018 Nov;157:67-84. doi: 10.1016/j.bcp.2018.08.016. Epub 2018 Aug 17
 
        The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies
        to improve on the poor current therapeutic outcomes.
 
         Fernández-Ruiz J.
 
         Br J Pharmacol. 2019 May;176(10):1370-1383. doi: 10.1111/bph.14382. Epub 2018 Jul 8
 
        Discovery of Homobivalent Bitopic Ligands of the Cannabinoid CB2 Receptor*.
 
          Morales P, Navarro G, Gómez-Autet M, Redondo L, Fernández-Ruiz J, Pérez-Benito L, Cordomí A, Pardo L, Franco R, Jagerovic N.
 
          Chemistry. 2020 Dec 4;26(68):15839-15842. doi: 10.1002/chem.202003389. Epub 2020 Nov 9
 
        BiP Heterozigosity Aggravates Pathological Deterioration in Experimental Amyotrophic Lateral Sclerosis.
 
         Gómez-Almería M, Burgaz S, Costas-Insua C, Rodríguez-Cueto C, Santos-García I, Rodríguez-Crespo I, García C, Guzmán M, de Lago E, Fernández-Ruiz J.
 
         Int J Mol Sci. 2021 Nov 20;22(22):12533. doi: 10.3390/ijms222212533
 
        Novel sulfenamides and sulfonamides based on pyridazinone and pyridazine scaffolds as CB1 receptor ligand antagonists.
 
         Murineddu G, Deligia F, Ragusa G, García-Toscano L, Gómez-Cañas M, Asproni B, Satta V, Cichero E, Pazos R, Fossa P, Loriga G, Fernández-Ruiz J, Pinna GA.
 
         Bioorg Med Chem. 2018 Jan 1;26(1):295-307. doi: 10.1016/j.bmc.2017.11.051. Epub 2017 Dec 2
 
       VCE-004.3, a cannabidiol aminoquinone derivative, prevents bleomycin-induced skin fibrosis and
        inflammation through PPARγ- and CB2 receptor-dependent pathways.
 
        Del Rio C, Cantarero I, Palomares B, Gómez-Cañas M, Fernández-Ruiz J, Pavicic C, García-Martín A, Luz Bellido M, Ortega-Castro R, Pérez-Sánchez C,
        López-Pedrera C, Appendino G, Calzado MA, Muñoz E.
 
       Br J Pharmacol. 2018 Oct;175(19):3813-3831. doi: 10.1111/bph.14450. Epub 2018 Aug 23
 
       Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice,
       a model of amyotrophic lateral sclerosis.
 
        Espejo-Porras F, García-Toscano L, Rodríguez-Cueto C, Santos-García I, de Lago E,Fernández-Ruiz J.
 
        Br J Pharmacol. 2019 May;176(10):1585-1600. doi: 10.1111/bph.14216. Epub 2018 May 6
 
       Analysis of endocannabinoid receptors and enzymes in the post-mortem motor cortex and spinal cord of amyotrophic lateral sclerosis patients.
 
        Espejo-Porras F, Fernández-Ruiz J, de Lago E.
 
        Amyotroph Lateral Scler Frontotemporal Degener. 2018 Aug;19(5-6):377-386. doi: 10.1080/21678421.2018.1425454. Epub 2018 Jan 15
 
       Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice,
       an experimental model of amyotrophic lateral sclerosis.
 
        Rodríguez-Cueto C, Santos-García I, García-Toscano L, Espejo-Porras F, Bellido M, Fernández-Ruiz J, Muñoz E, de Lago E.
 
        Biochem Pharmacol. 2018 Nov;157:217-226. doi: 10.1016/j.bcp.2018.07.049. Epub 2018 Aug 1
 
       Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease:
       possible involvement of different binding sites at the PPARγ receptor.
 
        García C, Gómez-Cañas M, Burgaz S, Palomares B, Gómez-Gálvez Y, Palomo-Garo C, Campo S, Ferrer-Hernández J, Pavicic C, Navarrete C, Luz Bellido M,
        García-Arencibia M, Ruth Pazos M, Muñoz E,Fernández-Ruiz J.
     
        J Neuroinflammation. 2018 Jan 16;15(1):19. doi: 10.1186/s12974-018-1060-5